Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Nivolumab with or without Ipilimumab or Relatlimab in Treating Patients with Unresectable, Metastatic, or Refractory Basal Cell Carcinoma

Trial Status: active

This phase II trial studies how well nivolumab with or without ipilimumab or relatlimab works in treating patients with basal cell carcinoma that cannot be removed by surgery (unresectable), has spread to other places in the body (metastatic), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, and relatlimab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.